ono-1301 and Amyotrophic-Lateral-Sclerosis

ono-1301 has been researched along with Amyotrophic-Lateral-Sclerosis* in 1 studies

Other Studies

1 other study(ies) available for ono-1301 and Amyotrophic-Lateral-Sclerosis

ArticleYear
Single injection of sustained-release prostacyclin analog ONO-1301-MS ameliorates hypoxic toxicity in the murine model of amyotrophic lateral sclerosis.
    Scientific reports, 2019, 03-27, Volume: 9, Issue:1

    Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by several pathologies including oxidative stress, apoptosis, neuroinflammation, and glutamate toxicity. Although multiple reports suggest that ischemia and hypoxia in the spinal cord plays a pivotal role in the pathogenesis of ALS, the precise role of hypoxia in disease progression remains unknown. In this study, we detected higher expression levels of Hypoxia-inducible factor 1-alpha (HIF-1α), a key regulator of cellular responses to hypoxia, in the spinal cord of ALS patients and in the transgenic mice overexpressing the familial ALS-associated G93A SOD1 mutation (mSOD1

    Topics: Adenosine Triphosphate; Amyotrophic Lateral Sclerosis; Animals; Blotting, Western; Disease Models, Animal; Epoprostenol; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Motor Neurons; Pyridines

2019